Dermatite Atopique
Aires thérapeutiques
-(1).jpg/jcr:content/image%20(1)%20(1).jpg)
Articles
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN
What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?
Advancing Treatment for Uncontrolled AD and PN: New Approaches
As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.
Découvrez le mode d’action unique du dupilumab
Dupixent est le premier traitement à moduler spécifiquement les mécanismes immunitaires clés de la dermatite atopique en inhibant les signaux IL-4 et IL-13, principaux facteurs de l’inflammation de type 2.1,2
The Long-Term Impact of Early-Onset Atopic Dermatitis
A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.
Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.
Éducation
DERM 360°
Clinical challenges to achieve long-term disease control within treatment of moderate to severe AD.
DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice
3rd of December 2024
Managing Atopic Dermatitis During Pregnancy and Breastfeeding
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Klas Agerberg, Uppsala University Hospital, Sweden
Managing Pediatric Atopic Dermatitis
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Hannah de Leye, UZ Brussel, Belgium
Managing Atopic Dermatitis in Patients with Comorbidities
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Jon Anders Halvorsen, Oslo, Norway
Managing Atopic Dermatitis in the Elderly
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Stine Simonsen, Copenhagen University Hospitals, Denmark
%20(1).svg)
